08-21-2013, 04:45 PM
Latest Drug launch by Biocon as a Solution to Psoriasis
Biocon on 10th August 2013 launched a new drug as a cure for Psoriasis.
Drug: ALZUMAb
Use: To treat Psoriasis
What is Psoriasis?
Psoriasis is a skin disease which is chronic in nature occurs as an over response of one’s own immune system against the skin cells.
Types of Psoriasis:
Plaque, Guttate, erythrodermic, pustular and inverse psoriasis
The drug ALZUMAb is effective against plaque Psoriasis
ALZUMAb
Humanized IgG1 Monoclonal antibody / anti- CD6 antibody
It is of biological origin
Target: CD6 Cells
Mode of Action: Attaches to CD6 cells and turns down T cell activation.
Salient Features of the drug
As the drug is of biological origin there is no involvement of any chemical process
The drug will be a remedy to Plaque Psoriasis for about 1 percent to 2 percent affected population in India.
Use of this drug in Psoriasis affected individual ensures a prolonged remission period of about 25 weeks to 28 weeks. So proves itself efficient against other available drugs for Psoriasis, the use of which gives a remission period only of about 5 weeks to 15 weeks.
How much one need to spend to reach ALZUMAb?
Rs. 7950 for a vial which is actually almost halve the rate compared to other Psoriasis drugs in the market. As discussed above, the longer remission period enhanced by the drug has significant effect on the amount to be spent on the drug.
Authority to Biocon to market this drug in India: Approved by Drugs Controller General of India
Biocon as its next step to market this product globally is in the process of seeking approval from FDA by filing an investigational new drug application.
The drug is expected to be a cure for few other ailments like rheumatoid arthritis, Psoriatic arthritis and multiple sclerosis by its manufacturer and the clinical trials is underway for the same.
Biocon on 10th August 2013 launched a new drug as a cure for Psoriasis.
Drug: ALZUMAb
Use: To treat Psoriasis
What is Psoriasis?
Psoriasis is a skin disease which is chronic in nature occurs as an over response of one’s own immune system against the skin cells.
Types of Psoriasis:
Plaque, Guttate, erythrodermic, pustular and inverse psoriasis
The drug ALZUMAb is effective against plaque Psoriasis
ALZUMAb
Humanized IgG1 Monoclonal antibody / anti- CD6 antibody
It is of biological origin
Target: CD6 Cells
Mode of Action: Attaches to CD6 cells and turns down T cell activation.
Salient Features of the drug
As the drug is of biological origin there is no involvement of any chemical process
The drug will be a remedy to Plaque Psoriasis for about 1 percent to 2 percent affected population in India.
Use of this drug in Psoriasis affected individual ensures a prolonged remission period of about 25 weeks to 28 weeks. So proves itself efficient against other available drugs for Psoriasis, the use of which gives a remission period only of about 5 weeks to 15 weeks.
How much one need to spend to reach ALZUMAb?
Rs. 7950 for a vial which is actually almost halve the rate compared to other Psoriasis drugs in the market. As discussed above, the longer remission period enhanced by the drug has significant effect on the amount to be spent on the drug.
Authority to Biocon to market this drug in India: Approved by Drugs Controller General of India
Biocon as its next step to market this product globally is in the process of seeking approval from FDA by filing an investigational new drug application.
The drug is expected to be a cure for few other ailments like rheumatoid arthritis, Psoriatic arthritis and multiple sclerosis by its manufacturer and the clinical trials is underway for the same.
![[+]](https://www.biotechnologyforums.com/images/netpen-pro/collapse_collapsed.png)